Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation MappingJulia Wulfkuhle, Emanuel F. Petricoin, Daniela Berg et al.|Clinical Cancer Research|2012Cited by 124
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A. Cohen, Arjun Jeyarajah, Eleanor C. Brockbank et al.|Gynecologic Oncology|2019Cited by 121
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancerStefanie Seitz, Holger Bronger|British Journal of Cancer|2022Cited by 69
The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>Tobias Dreyer, Holger Bronger|Cancer Immunology Research|2021Cited by 23